Stock SGP SCHERING-PLOUGH
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News SCHERING-PLOUGH

Equities

SGP

US8066051017

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for SCHERING-PLOUGH
2009 SCHERING-PLOUGH : Schering profit rises RE
2009 SCHERING-PLOUGH : profit beats views; cost cuts help RE

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SCHERING-PLOUGH : Announces Sponsorship of Rabies-Control Projects in India
PR
SCHERING-PLOUGH : Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
PR
SCHERING-PLOUGH : U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma
PR
SCHERING-PLOUGH : Standard & Poor's Announces Changes to U.S. Indices
PR
SCHERING-PLOUGH : Reports Financial Results for 2009 Third Quarter
PR
SCHERING-PLOUGH : Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Concept Study
PR
SCHERING-PLOUGH : Schedules Conference Call Webcast For 2009 Third Quarter Earnings
PR
SCHERING-PLOUGH : SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
PR
SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
PR
SCHERING-PLOUGH : Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
PR
SCHERING-PLOUGH : Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
PR
SCHERING-PLOUGH : New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day
PR
SCHERING-PLOUGH : Announces Two European Filings
PR
SCHERING-PLOUGH : ANNOUNCES FDA APPROVAL OF SAPHRIS(R) (asenapine): for acute treatment of schizophrenia in adults and manic or mixed episodes of bipolar I disorder with or without psychotic features in adults
PR
SCHERING-PLOUGH : Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults
PR
SCHERING-PLOUGH : Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)
PR
SCHERING-PLOUGH : Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours
PR
SCHERING-PLOUGH : PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration
PR
SCHERING-PLOUGH : Shareholders Approve Merger With Merck
PR
SCHERING-PLOUGH : to Webcast Special Meeting of Shareholders
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGP Stock
  4. News SCHERING-PLOUGH